US 11,926,674 B2
Anti-Jagged2 antibodies and methods of use
Yvonne Chinn, Foster City, CA (US); Julie Q. Hang, San Jose, CA (US); Christian W. Siebel, Berkeley, CA (US); Yan Wu, Foster City, CA (US); and Daniel Lafkas, San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Oct. 30, 2020, as Appl. No. 17/085,750.
Application 17/085,750 is a division of application No. 15/997,299, filed on Jun. 4, 2018, granted, now 10,858,440.
Application 15/997,299 is a division of application No. 15/297,390, filed on Oct. 19, 2016, granted, now 10,011,661, issued on Jul. 3, 2018.
Application 15/297,390 is a division of application No. 14/619,930, filed on Feb. 11, 2015, granted, now 9,518,121, issued on Dec. 13, 2016.
Claims priority of provisional application 61/939,110, filed on Feb. 12, 2014.
Prior Publication US 2021/0206871 A1, Jul. 8, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 9 Claims
 
1. A method of treating goblet cell metaplasia and/or excess mucus, the method comprising administering to a subject in need thereof an effective amount of an antibody that binds to human Jagged2, wherein the antibody comprises:
a) amino acid residues 31-35 of SEQ ID NO: 88 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 88 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 88 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 100 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 100 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 100 as CDRL3;
b) amino acid residues 31-35 of SEQ ID NO: 89 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 89 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 89 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 101 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 101 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 101 as CDRL3;
c) amino acid residues 31-35 of SEQ ID NO: 90 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 90 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 90 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 102 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 102 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 102 as CDRL3; or
d) amino acid residues 31-35 of SEQ ID NO: 91 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 91 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 91 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 103 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 103 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 103 as CDRL3,
wherein the amino acid residue numbering is according to Kabat, and
wherein the goblet cell metaplasia and/or excess mucus is associated with asthma or chronic obstructive pulmonary disease (COPD).